MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

11.38 -0.03 (-0.26%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 29, 2025

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

Via Benzinga

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 29, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1...

Via Benzinga

Topics Stocks

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

September 29, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? ↗

September 29, 2025

RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive.

Via Stocktwits

MoonLake Immunotherapeutics Stock Draws Buzz After Skin Drug’s Phase 3 Trial Data — Retail Speculates Buyout, Bigger Gains ↗

September 28, 2025

Via Stocktwits

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗

September 29, 2025

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its...

Via Benzinga

2 Small-Cap Biotech Stocks Well Positioned for a Breakout ↗

August 27, 2025

Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.

Via The Motley Fool

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗

June 13, 2025

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Via Benzinga

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗

June 06, 2025

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Via Benzinga

Topics Bankruptcy

Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday ↗

June 03, 2025

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

June 03, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover ↗

June 03, 2025

The deal is being discussed ahead of key data from MoonLake in patients with a skin disease.

Via Investor's Business Daily

Tuesday's pre-market session: top gainers and losers ↗

June 03, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 03, 2025

Via Benzinga

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report ↗

June 03, 2025

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

Via Benzinga

Topics Intellectual Property

Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

June 03, 2025

Via Benzinga

US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&P 500's 'Recovery Is Real' And Not A 'Bull Trap' Or 'Bear Market Rally' ↗

June 03, 2025

U.S. stock futures fell on Tuesday after a higher close on Monday. Futures of major benchmark indices declined in premarket.

Via Benzinga

Topics Stocks

Dollar General, Signet Jewelers And 3 Stocks To Watch Heading Into Tuesday ↗

June 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 02, 2025

Via Benzinga

This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

March 18, 2025

Via Benzinga

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? ↗

January 17, 2025

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Via Stocktwits

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

January 08, 2025

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

June 10, 2024

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

May 16, 2024

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 ↗

May 07, 2024

MLTX stock results show that MoonLake missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

April 10, 2024

From Komodo Health

Via Business Wire

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 10, 2024

Via Benzinga

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test ↗

March 11, 2024

The company tested its psoriatic arthritis drug over 24 weeks against Humira.

Via Investor's Business Daily

Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today? ↗

March 11, 2024

Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.

Via Benzinga

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

March 10, 2024

From MoonLake Immunotherapeutics AG

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.